Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6170) 6170
Publication (493) 493
Book Review (22) 22
Book Chapter (17) 17
Conference Proceeding (9) 9
Book / eBook (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4702) 4702
urokinase-type plasminogen activator - metabolism (3677) 3677
animals (2594) 2594
female (1598) 1598
urokinase-type plasminogen activator - genetics (1376) 1376
male (1280) 1280
mice (1262) 1262
index medicus (1141) 1141
urokinase (1026) 1026
biochemistry & molecular biology (1021) 1021
receptors, urokinase plasminogen activator (1007) 1007
expression (950) 950
oncology (942) 942
cells, cultured (812) 812
receptors, cell surface - metabolism (727) 727
plasminogen activator inhibitor 1 - metabolism (704) 704
plasminogen-activator (687) 687
plasminogen activators - metabolism (661) 661
cell biology (647) 647
plasminogen - metabolism (647) 647
tissue plasminogen activator - metabolism (637) 637
middle aged (620) 620
kinetics (611) 611
fibrinolysis (601) 601
adult (593) 593
tumor cells, cultured (587) 587
urokinase-type plasminogen activator - biosynthesis (586) 586
receptor (552) 552
cell line, tumor (546) 546
cell line (539) 539
metastasis (531) 531
hematology (530) 530
urokinase-type plasminogen activator - pharmacology (519) 519
invasion (516) 516
urokinase-type plasminogen activator - antagonists & inhibitors (507) 507
aged (496) 496
rats (492) 492
cancer (489) 489
fibrinolysin - metabolism (484) 484
neoplasm invasiveness (478) 478
rna, messenger - metabolism (471) 471
immunohistochemistry (433) 433
molecular sequence data (423) 423
urokinase-type plasminogen activator (418) 418
cells (399) 399
system (382) 382
time factors (367) 367
amino acid sequence (363) 363
upa (359) 359
peripheral vascular disease (344) 344
in-vitro (341) 341
gene expression (338) 338
protein binding (337) 337
urokinase receptor (327) 327
plasminogen activator inhibitor 1 - genetics (325) 325
endothelial-cells (322) 322
signal transduction (319) 319
enzyme activation (318) 318
enzyme-linked immunosorbent assay (315) 315
transfection (313) 313
cell movement - drug effects (311) 311
fibrin - metabolism (308) 308
binding (306) 306
molecular weight (306) 306
blotting, western (301) 301
rna, messenger - genetics (300) 300
electrophoresis, polyacrylamide gel (298) 298
gene-expression (293) 293
prognosis (290) 290
receptors, cell surface - genetics (288) 288
urokinase-type plasminogen activator - analysis (285) 285
matrix metalloproteinases (284) 284
dose-response relationship, drug (281) 281
recombinant proteins - metabolism (279) 279
binding sites (276) 276
breast-cancer (270) 270
in-vivo (268) 268
migration (268) 268
base sequence (265) 265
plasminogen activators (265) 265
cell movement (263) 263
mice, inbred c57bl (262) 262
urokinase-type plasminogen activator - chemistry (261) 261
angiogenesis (258) 258
extracellular-matrix (258) 258
proteins (256) 256
urokinase-type plasminogen activator - physiology (256) 256
breast neoplasms - metabolism (249) 249
research article (247) 247
growth (246) 246
receptors, urokinase plasminogen activator - metabolism (241) 241
analysis (239) 239
breast neoplasms - pathology (239) 239
reverse transcriptase polymerase chain reaction (239) 239
research (238) 238
messenger-rna (234) 234
plasminogen activator (233) 233
fibrinolysis - drug effects (227) 227
tissue plasminogen activator - genetics (225) 225
neoplasm metastasis (224) 224
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5907) 5907
Chinese (90) 90
Japanese (54) 54
Russian (54) 54
French (22) 22
German (21) 21
Polish (14) 14
Spanish (9) 9
Czech (1) 1
Danish (1) 1
Italian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimers disease
by Bi Oh, Shin and Suh, Nayoung and Kim, Inki and Lee, Joo-Yong
Brain Research, ISSN 0006-8993, 02/2015, Volume 1597, pp. 159 - 167
Plasminogen activators (PAs), which convert plasminogen into the fibrinolytic protease plasmin, may initiate the degradation of amyloid-β (Aβ) to suppress the... 
Amyloid degrading enzymes | Amyloid pathogenesis | Amyloid plaques | Plasmin | SYSTEM | PROTEIN | STIMULATION | A-BETA-42 | CLEAVAGE | NEUROTOXICITY | NEUROSCIENCES | IN-VITRO | GENE | A-BETA | DEGRADATION | Neurons - pathology | Tissue Plasminogen Activator - metabolism | Neuroglia - pathology | Humans | Cerebral Cortex - pathology | Cerebral Cortex - metabolism | Alzheimer Disease - pathology | Amyloid beta-Peptides - metabolism | Amyloid beta-Protein Precursor - metabolism | Female | Neurons - metabolism | Fibrinolysin - metabolism | Disease Models, Animal | Plaque, Amyloid - pathology | Mice, Inbred C57BL | Mice, Transgenic | Hippocampus - pathology | Hippocampus - metabolism | Amyloid beta-Protein Precursor - genetics | Animals | Urokinase-Type Plasminogen Activator - metabolism | Alzheimer Disease - metabolism | Neuroglia - metabolism | Plaque, Amyloid - metabolism | Serpin E2 - metabolism | Aging - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in Vivo
by Sai MuraliKrishna Pulukuri and Christopher S. Gondi and Sajani S. Lakka and Aman Jutla and Norman Estes and Meena Gujrati and Jasti S. Rao
Journal of Biological Chemistry, ISSN 0021-9258, 10/2005, Volume 280, Issue 43, pp. 36529 - 36540
The invasive ability of tumor cells plays a key role in prostate cancer metastasis and is a major cause of treatment failure. Urokinase plasminogen... 
MIGRATION | VITRO | GROWTH-FACTOR-RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | MOUSE MODEL | GENE-EXPRESSION | DOWN-REGULATION | UPA PROMOTER | TUMOR-GROWTH | ANTISENSE OLIGONUCLEOTIDES | CATHEPSIN-B | Laminin - pharmacology | Neoplasm Transplantation | Prostatic Neoplasms - metabolism | Cell Proliferation | Humans | Extracellular Matrix - metabolism | Collagen - chemistry | Immunoblotting | Male | Proteoglycans - chemistry | Neoplasm Metastasis | Transfection | RNA Interference | Time Factors | Collagen - pharmacology | Prostatic Neoplasms - pathology | Signal Transduction | Cell Survival | Neoplasm Invasiveness | Electrophoresis, Polyacrylamide Gel | Gene Silencing | Tetrazolium Salts - pharmacology | Urokinase-Type Plasminogen Activator - genetics | Reverse Transcriptase Polymerase Chain Reaction | Plasmids - metabolism | Animals | Mitogen-Activated Protein Kinase 3 - metabolism | Proteoglycans - pharmacology | Urokinase-Type Plasminogen Activator - metabolism | Mice, Nude | Cell Line, Tumor | Laminin - chemistry | Mice | Thiazoles - pharmacology | Neoplasms - pathology | Drug Combinations | Microscopy, Fluorescence | Apoptosis | Mitogen-Activated Protein Kinase 1 - metabolism | RNA, Small Interfering - metabolism | RNAi | uPAR (uPA receptor) | shRNA (small hairpin RNA) | uPA (urokinaseplasminogen activator) | survival | siRNA (small interfering RNA) | prostate cancer | invasion | uPA and uPAR | ANOVA (analysis of variance) | RNAi (RNA interference) | RT (reverse transcription) | TPBS (tween-20 (0.1%) phospate buffered saline) | BSA (bovine serum albumin)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
by Duffy, M.J and Harbeck, N and Nap, M and Molina, R and Nicolini, A and Senkus, E and Cardoso, F
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 75, pp. 284 - 298
Abstract Biomarkers play an essential role in the management of patients with invasive breast cancer. For selecting patients likely to respond to endocrine... 
Hematology, Oncology and Palliative Medicine | Biomarkers | Breast cancer | EGTM | Guidelines | Gene signatures | COST-EFFECTIVENESS ANALYSIS | PLASMINOGEN-ACTIVATOR UPA | PROGNOSTIC IMPACT | LATE DISTANT RECURRENCE | ESTROGEN-RECEPTOR STATUS | SYSTEMIC THERAPY | PAM50 RISK | ONCOLOGY | ADJUVANT ENDOCRINE THERAPY | PROGESTERONE-RECEPTOR | AMERICAN SOCIETY | Receptors, Estrogen - metabolism | Prognosis | Humans | Receptor, ErbB-2 - metabolism | Gene Expression Profiling - methods | Ki-67 Antigen - metabolism | Neoplasm Proteins - metabolism | Genetic Testing - methods | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Breast Neoplasms - therapy | Plasminogen Activator Inhibitor 1 - metabolism | Urokinase-Type Plasminogen Activator - metabolism | Biomarkers, Tumor - metabolism | Female | Practice Guidelines as Topic | Medical research | Medical colleges | Estrogen | Medicine, Experimental | Progesterone | Metastasis | Biological markers
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Transforming growth factor‐β, matrix metalloproteinases, and urokinase‐type plasminogen activator interaction in the cancer epithelial to mesenchymal transition
by Santibanez, Juan F and Obradović, Hristina and Kukolj, Tamara and Krstić, Jelena
Developmental Dynamics, ISSN 1058-8388, 03/2018, Volume 247, Issue 3, pp. 382 - 395
Transforming growth factor‐β (TGF‐β) is a pleiotropic factor that acts as a tumor suppressor in the early stages, while it exerts tumor promoting activities in... 
MMP | tumor progression | extracellular matrix proteinases | invasion | metastasis | stroma | uPA | EMT | TGF‐beta | TGF-beta | Animals | Urokinase-Type Plasminogen Activator - metabolism | Humans | Epithelial-Mesenchymal Transition | Transforming Growth Factor beta - physiology | Extracellular Matrix - metabolism | Matrix Metalloproteinases - metabolism | Neoplasms - pathology | Transforming Growth Factor beta - metabolism | Disease Progression | Cell Movement
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice
by Hijazi, Nuha and Fanne, Rami Abu and Abramovitch, Rinat and Yarovoi, Serge and Higazi, Muhamed and Abdeen, Suhair and Basheer, Maamon and Maraga, Emad and Cines, Douglas B and Higazi, Abd Al-Roof
Blood, ISSN 0006-4971, 04/2015, Volume 125, Issue 16, pp. 2558 - 2567
Persistent intracerebral hemorrhage (ICH) is amajor cause of death and disability after traumatic brain injury (TBI) for which no medical treatment is... 
RECOMMENDED RESEARCH PRIORITIES | TRANEXAMIC ACID | NATIVE GLU | CLOSED-HEAD INJURY | NERVOUS-SYSTEM | LYS HUMAN-PLASMINOGEN | KNOWLEDGE GAPS | TISSUE | RECEPTOR | HEMATOLOGY | BINDING | Cerebral Hemorrhage - metabolism | Fibrinolysis - drug effects | Tissue Plasminogen Activator - metabolism | Humans | Tranexamic Acid - pharmacology | Brain Injuries - complications | Male | Plasminogen - metabolism | Cerebral Hemorrhage - genetics | Tissue Plasminogen Activator - genetics | Brain - metabolism | Brain - blood supply | Plasminogen Activator Inhibitor 1 - metabolism | Time Factors | Brain Injuries - blood | Plasminogen Activator Inhibitor 1 - genetics | Cerebral Hemorrhage - etiology | Mice, Inbred C57BL | Urokinase-Type Plasminogen Activator - genetics | Mice, Knockout | Animals | Urokinase-Type Plasminogen Activator - metabolism | Antifibrinolytic Agents - pharmacology | Protein Binding | Mutation | Fibrin - metabolism | Thrombosis and Hemostasis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text UPA and PAI-1 as biomarkers in breast cancer: Validated for clinical use in level-of-evidence-1 studies
by Duffy, Michael J and McGowan, Patricia M and Harbeck, Nadia and Thomssen, Christoph and Schmitt, Manfred
Breast Cancer Research, ISSN 1465-5411, 08/2014, Volume 16, Issue 4, p. 428
Urokinase plasminogen activator (uPA) is an extracellular matrix-degrading protease involved in cancer invasion and metastasis, interacting with plasminogen... 
ADJUVANT CHEMOTHERAPY | TYPE-1 INHIBITOR | PROGNOSTIC-FACTORS | TUMOR-MARKERS | DECISION-MAKING | ONCOLOGY | RISK GROUP DISCRIMINATION | EARLY RELAPSE | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | UROKINASE-TYPE | AMERICAN SOCIETY | Urokinase-Type Plasminogen Activator - antagonists & inhibitors | Reproducibility of Results | Prognosis | Humans | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Molecular Targeted Therapy | Biomarkers, Tumor | Breast Neoplasms - drug therapy | Plasminogen Activator Inhibitor 1 - blood | Breast Neoplasms - metabolism | Animals | Plasminogen Activator Inhibitor 1 - metabolism | Urokinase-Type Plasminogen Activator - metabolism | Breast Neoplasms - blood | Female | Antineoplastic Agents - pharmacology | Breast Neoplasms - diagnosis | Urokinase-Type Plasminogen Activator - blood | Chemotherapy | Oncology, Experimental | Development and progression | Metastasis | Research | Biological markers | Cancer | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer
by Xie, C and Jiang, X.H and Zhang, J.T and Sun, T.T and Dong, J.D and Sanders, A.J and Diao, R.Y and Wang, Y and Fok, K.L and Tsang, L.L and Yu, M.K and Zhang, X.H and Chung, Y.W and Ye, L and Zhao, M.Y and Guo, J.H and Xiao, Z.J and Lan, H.Y and Ng, C.F and Lau, K.M and Cai, Z.M and Jiang, W.G and Chan, H.C
Oncogene, ISSN 0950-9232, 05/2013, Volume 32, Issue 18, pp. 2282 - 2291
Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is expressed in the epithelial cells of a wide range of organs/tissues from which most cancers... 
CFTR | miR-193b | uPA | MUC4 EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | PANCREATIC ADENOCARCINOMA | CELL MIGRATION | MESENCHYMAL TRANSITION | MIR-200 FAMILY | CELL BIOLOGY | TRANSMEMBRANE CONDUCTANCE REGULATOR | BREAST-CANCER | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | GENETICS & HEREDITY | NF-KAPPA-B | CYSTIC-FIBROSIS GENE | Prostatic Neoplasms - metabolism | Receptors, Urokinase Plasminogen Activator - immunology | Humans | Gene Expression Regulation, Neoplastic | Molecular Sequence Data | Male | Cell Movement - genetics | Gene Knockdown Techniques | Prostatic Neoplasms - genetics | Base Sequence | Female | Urokinase-Type Plasminogen Activator - immunology | Prostatic Neoplasms - pathology | Down-Regulation | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Urokinase-Type Plasminogen Activator - genetics | Receptors, Urokinase Plasminogen Activator - metabolism | Xenograft Model Antitumor Assays | Animals | Urokinase-Type Plasminogen Activator - metabolism | Mice, Nude | Cell Line, Tumor | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Mice | MicroRNAs - genetics | Receptors, Urokinase Plasminogen Activator - genetics | Urokinase | Tissue plasminogen activator | Physiological aspects | Development and progression | Tumor suppressor genes | Genetic aspects | Research | Prostate cancer | Cystic fibrosis | Membranes | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
by Gupta, Kamlesh K and Donahue, Deborah L and Sandoval-Cooper, Mayra J and Castellino, Francis J and Ploplis, Victoria A
Scientific Reports, ISSN 2045-2322, 12/2017, Volume 7, Issue 1, pp. 365 - 11
Plasminogen activator inhibitor-1 (PAI-1) is known to protect mice against cardiac fibrosis. It has been speculated that PAI-1 may regulate cardiac fibrosis by... 
GENETIC DEFICIENCY | TGF-BETA | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | PAI-1 | GENERATION | TISSUES | Gene Expression | Mice, Inbred C57BL | Smad2 Protein - metabolism | Male | Myocardium - pathology | Plasminogen - metabolism | Urokinase-Type Plasminogen Activator - genetics | Heart Diseases - enzymology | Mice, Knockout | Heart Diseases - etiology | Phenotype | Animals | Plasminogen Activator Inhibitor 1 - metabolism | Urokinase-Type Plasminogen Activator - metabolism | Myocardium - metabolism | Fibrosis | Hypertension - complications | Plasminogen Activator Inhibitor 1 - genetics | Fibrinolysin - metabolism | Heart Diseases - pathology | Disease Models, Animal | Heart | Hypertension | Aldosterone | Plasmin | Proenzymes | U-Plasminogen activator | Smad2 protein | Rodents | Plasminogen activator inhibitors | Angiotensin | Angiotensin II | Heart diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies
by Su, Shih-Chi and Lin, Chiao-Wen and Yang, Wei-En and Fan, Wen-Lang and Yang, Shun-Fa
Expert Opinion on Therapeutic Targets, ISSN 1472-8222, 05/2016, Volume 20, Issue 5, pp. 551 - 566
Introduction: The urokinase plasminogen activator (uPA) system, comprising the serine protease uPA, its cognate receptor, uPAR, and two endogenous inhibitors,... 
urokinase plasminogen activator (uPA) | Angiogenesis | extracellular matrix (ECM) | malignancy | metastasis | matrix metalloprotease (MMP) | integrin | Integrin | Extracellular matrix (ECM) | Matrix metalloprotease (MMP) | Malignancy | Urokinase plasminogen activator (uPA) | Metastasis | RECEPTOR-RELATED PROTEIN | BETA-INDUCIBLE ELEMENTS | EPITHELIAL-MESENCHYMAL TRANSITION | AMINO-TERMINAL FRAGMENT | LEWIS-LUNG-CARCINOMA | MATRIX-METALLOPROTEINASE INHIBITORS | PHARMACOLOGY & PHARMACY | DEPENDENT ANTHRAX TOXIN | SMOOTH-MUSCLE-CELLS | PRIMARY TUMOR-GROWTH | CANCER CELL INVASION | Neoplasms - metabolism | Biomarkers, Tumor - metabolism | Animals | Urokinase-Type Plasminogen Activator - metabolism | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview
by Mekkawy, Ahmed H and Pourgholami, Mohammad H and Morris, David L
Medicinal Research Reviews, ISSN 0198-6325, 09/2014, Volume 34, Issue 5, pp. 918 - 956
Currently, there are several studies supporting the role of urokinase‐type plasminogen activator (uPA) system in cancer. The association of uPA to its receptor... 
cancer | invasion | metastasis | prognosis | urokinase | Urokinase | Prognosis | Metastasis | Invasion | Cancer | PANCREATIC DUCTAL ADENOCARCINOMA | RECEPTOR-BOUND UROKINASE | CHEMISTRY, MEDICINAL | MESSENGER-RNA EXPRESSION | CELL LUNG-CANCER | EPITHELIAL-MESENCHYMAL TRANSITION | LYMPH-NODE INVOLVEMENT | DISSEMINATED TUMOR-CELLS | INCREASED PLASMA-LEVELS | SINGLE-CHAIN UROKINASE | PHARMACOLOGY & PHARMACY | ENDOTHELIAL GROWTH-FACTOR | Urokinase-Type Plasminogen Activator - metabolism | Humans | Neoplasms - enzymology | Neoplasms - classification | Urokinase-Type Plasminogen Activator - chemistry | Neoplasms - physiopathology | Disease Progression | Development and progression
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights